Status:
NOT_YET_RECRUITING
Safety and Efficacy of Two Oral Tinidazole Regimens for Refractory Trichomonas Vaginitis
Lead Sponsor:
Shangrong Fan
Conditions:
Trichomonas Vaginitis
Eligibility:
FEMALE
18-55 years
Phase:
NA
Brief Summary
We compare two oral tinidazole regimens for refractory trichomonas vaginitis.
Detailed Description
Refractory trichomonas vaginitis has become a clinical problem, which has a direct impact on the health and life of patients. Refractory trichomonas vaginitis is mainly caused by drug resistance of tr...
Eligibility Criteria
Inclusion
- Women be at least 18 years of age
- Failure of conventional treatment (recommended by guidelines including tinidazole, 2g once daily for 5-7 days)
Exclusion
- Allergy to metronidazole or tinidazol
- Pregnant or nursing
- HIV or other chronic disease
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05383521
Start Date
December 1 2025
End Date
December 30 2025
Last Update
June 11 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China, 518000
2
Beijing Obstetrics and Gynecology Hospital,Capital Medical University
Beijing, China
3
Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University
Beijing, China
4
Peking University First Hospital
Beijing, China